233 related articles for article (PubMed ID: 21928112)
1. The promoter hypermethylation status of GATA6, MGMT, and FHIT in glioblastoma.
Cecener G; Tunca B; Egeli U; Bekar A; Tezcan G; Erturk E; Bayram N; Tolunay S
Cell Mol Neurobiol; 2012 Mar; 32(2):237-44. PubMed ID: 21928112
[TBL] [Abstract][Full Text] [Related]
2. MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma.
Skiriute D; Vaitkiene P; Saferis V; Asmoniene V; Skauminas K; Deltuva VP; Tamasauskas A
BMC Cancer; 2012 Jun; 12():218. PubMed ID: 22672670
[TBL] [Abstract][Full Text] [Related]
3. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.
Ohka F; Natsume A; Motomura K; Kishida Y; Kondo Y; Abe T; Nakasu Y; Namba H; Wakai K; Fukui T; Momota H; Iwami K; Kinjo S; Ito M; Fujii M; Wakabayashi T
PLoS One; 2011; 6(8):e23332. PubMed ID: 21829728
[TBL] [Abstract][Full Text] [Related]
4. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.
Mellai M; Monzeglio O; Piazzi A; Caldera V; Annovazzi L; Cassoni P; Valente G; Cordera S; Mocellini C; Schiffer D
J Neurooncol; 2012 May; 107(3):617-31. PubMed ID: 22287028
[TBL] [Abstract][Full Text] [Related]
5. Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population.
Sinha R; Hussain S; Mehrotra R; Kumar RS; Kumar K; Pande P; Doval DC; Basir SF; Bharadwaj M
PLoS One; 2013; 8(4):e60142. PubMed ID: 23573237
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic mechanisms in glioblastoma multiforme.
Nagarajan RP; Costello JF
Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
[TBL] [Abstract][Full Text] [Related]
7. MGMT gene promoter methylation in pediatric glioblastomas.
Srivastava A; Jain A; Jha P; Suri V; Sharma MC; Mallick S; Puri T; Gupta DK; Gupta A; Sarkar C
Childs Nerv Syst; 2010 Nov; 26(11):1613-8. PubMed ID: 20585787
[TBL] [Abstract][Full Text] [Related]
8. Dual MGMT inactivation by promoter hypermethylation and loss of the long arm of chromosome 10 in glioblastoma.
Richard S; Tachon G; Milin S; Wager M; Karayan-Tapon L
Cancer Med; 2020 Sep; 9(17):6344-6353. PubMed ID: 32666673
[TBL] [Abstract][Full Text] [Related]
9. Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma.
Banzai C; Nishino K; Quan J; Yoshihara K; Sekine M; Yahata T; Tanaka K;
Int J Clin Oncol; 2014 Feb; 19(1):127-32. PubMed ID: 23494221
[TBL] [Abstract][Full Text] [Related]
10.
Arora I; Gurav M; Rumde R; Dhanavade S; Kadam V; Kurani H; Shetty O; Goda JS; Shetty P; Moiyadi A; Gupta T; Jalali R; Epari S
Neurol India; 2018; 66(4):1106-1114. PubMed ID: 30038102
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of methylenetetrahydrofolate reductase and promoter methylation of MGMT and FHIT genes in diffuse large B cell lymphoma risk in Middle East.
Siraj AK; Ibrahim M; Al-Rasheed M; Bu R; Bavi P; Jehan Z; Abubaker J; Murad W; Al-Dayel F; Ezzat A; El-Solh H; Uddin S; Al-Kuraya K
Ann Hematol; 2007 Dec; 86(12):887-95. PubMed ID: 17712558
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme.
Oberstadt MC; Bien-Möller S; Weitmann K; Herzog S; Hentschel K; Rimmbach C; Vogelgesang S; Balz E; Fink M; Michael H; Zeden JP; Bruckmüller H; Werk AN; Cascorbi I; Hoffmann W; Rosskopf D; Schroeder HW; Kroemer HK
BMC Cancer; 2013 Dec; 13():617. PubMed ID: 24380367
[TBL] [Abstract][Full Text] [Related]
13. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
14. Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.
Jiang S; Rui Q; Wang Y; Heo HY; Zou T; Yu H; Zhang Y; Wang X; Du Y; Wen X; Chen F; Wang J; Eberhart CG; Zhou J; Wen Z
Eur Radiol; 2018 May; 28(5):2115-2123. PubMed ID: 29234914
[TBL] [Abstract][Full Text] [Related]
15. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.
Rivera AL; Pelloski CE; Gilbert MR; Colman H; De La Cruz C; Sulman EP; Bekele BN; Aldape KD
Neuro Oncol; 2010 Feb; 12(2):116-21. PubMed ID: 20150378
[TBL] [Abstract][Full Text] [Related]
16. MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA.
Lee JY; Park CK; Park SH; Wang KC; Cho BK; Kim SK
Childs Nerv Syst; 2011 Nov; 27(11):1877-83. PubMed ID: 21789683
[TBL] [Abstract][Full Text] [Related]
17. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation profile of RASSF1A, FHIT, and sFRP1 in intracranial primitive neuroectodermal tumors.
Chang Q; Pang JC; Li KK; Poon WS; Zhou L; Ng HK
Hum Pathol; 2005 Dec; 36(12):1265-72. PubMed ID: 16311119
[TBL] [Abstract][Full Text] [Related]
19. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.
Shamsara J; Sharif S; Afsharnezhad S; Lotfi M; Raziee HR; Ghaffarzadegan K; Moradi A; Rahighi S; Behravan J
Cancer Invest; 2009 Oct; 27(8):825-9. PubMed ID: 19544111
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation of RASSF1A, MGMT, and HIC-1 genes in benign and malignant colorectal tumors.
Abouzeid HE; Kassem AM; Abdel Wahab AH; El-mezayen HA; Sharad H; Abdel Rahman S
Tumour Biol; 2011 Oct; 32(5):845-52. PubMed ID: 21274674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
